Australia markets closed

HCM Aug 2024 20.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
3.20000.0000 (0.00%)
At close: 09:35AM EDT
Full screen
Previous close3.2000
Open3.2000
Bid0.4500
Ask3.3000
Strike20.00
Expiry date2024-08-16
Day's range3.2000 - 3.2000
Contract rangeN/A
Volume1
Open interest5
  • GlobeNewswire

    HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

    — Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZAQLA® (fruquintinib) is the first novel targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade — HONG KONG, SHANGHAI and FLORHAM PARK, N.J., June 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that its partner Takeda (TSE:4502/​NYSE:TAK) has receive

  • GlobeNewswire

    HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology

    — Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior lines of therapies or prior TPO/TPO-RA1 exposure — — Data supported regulatory submission in China accepted in January 2024 — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that resul

  • GlobeNewswire

    HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignancies in China. The first patient received their first dose on May 31, 2024. This is a Phase I, multicenter, open-label clinical study to evaluate the safety, pharmacokinetics and efficacy of HMPL-506 in patients with hemato